ArticleFrontiers in cellular and infection microbiology2024
Investigation on the mechanisms of carbapenem resistance among the non-carbapenemase-producing carbapenem-resistant
Article in Frontiers in cellular and infection microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Prevalence and molecular typing of carbapenem-resistant Enterobacterales in a secondary-care hospital in Jazan region, Saudi Arabia.New microbes and new infections · 2026Article
- Genomic Characterisation of Carbapenem-Resistant Klebsiella pneumoniae and Enterobacter hormaechei Clinical Isolates from Nigeria: Evidence of Resistance, Virulence, and Putative Plasmid-Mediated Gene Sharing.Current microbiology · 2026Article
- Rising Carbapenem MICs and Clinical Dose Optimization: Bridging Resistance Surveillance and Pharmacokinetic/Pharmacodynamic Strategies.Antibiotics (Basel, Switzerland) · 2026Review
- ESBL and carbapenemase-producing enteric pathogens in animal-origin foods: a one health perspective.Folia microbiologica · 2026Review
- Carbapenem resistance and hypervirulence iniScience · 2026Review
- Resistance, Virulence, and Molecular Epidemiology of Carbapenem-ResistantMicroorganisms · 2026Article
- A comparative genomic approach to identify determinants of meropenem resistance inFrontiers in microbiology · 2026Article
- Comparative Genomic and Resistance Analysis of ST859-KL19 and ST11 Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Impact of ompK35 and ompK36 downregulation on antibiotic resistance in clinical carbapenem-resistant Klebsiella pneumoniae isolates.Folia microbiologica · 2025Article
- Emergence of ST11-KL64 carbapenem-resistant hypervirulent Klebsiella Pneumoniae isolates harboring blaBMC infectious diseases · 2025Article
- Genome Sequencing and Comparative Genomic Analysis of Multidrug-ResistantInfection and drug resistance · 2025Article
- Clinical Characterization, Risk Factors, and Mortality in Patients with Carbapenem-Resistant HypervirulentInfection and drug resistance · 2025Article
- Epidemiological and molecular characteristics of carbapenem-resistant Klebsiella pneumoniae from pediatric patients in Henan, China.Annals of clinical microbiology and antimicrobials · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In Malaysia, an increase in non-carbapenemase-producing carbapenem-resistant Methods: All four NC-CRKP were subjected to whole-genome sequencing, followed by comparative genomic and phylogenetic analyses. Results: Multi-locus sequence typing (MLST) analysis divided the four NC-CRKP into different sequence types: ST392, ST45, ST14, and ST5947. Neither major nor rare carbapenemase genes were detected. Given the presence of non-carbapenemase β-lactamase in all isolates, we further investigated the potential mechanisms of resistance by identifying related chromosomal mutations. Deletion mutation was detected in the cation efflux system protein CusF. Insertion mutation was identified in the nickel/cobalt efflux protein RcnA. Missense mutation of ompK36 porin was detected in two isolates, while the loss of ompK36 porin was observed in another two isolates. Conclusions: This study revealed that NC-CRKP may confer carbapenem resistance through a combination of non-carbapenemase β-lactamase and potential chromosomal mutations including missense mutation or loss of ompK36 porin and/or a frameshift missense mutation in efflux pump systems, such as cation efflux system protein CusF and nickel/cobalt efflux protein RcnA. Our findings highlighted the significance of implementing whole-genome sequencing into clinical practice to promote the surveillance of carbapenem resistance mechanisms among NC-CRKP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.